MedPath

Efficacy and Safety of Cefditoren Pivoxil Versus Ciprofloxacin in Acute Uncomplicated Cystitis

Phase 3
Completed
Conditions
Urinary Tract Infections
Interventions
Registration Number
NCT00598403
Lead Sponsor
Tedec-Meiji Farma, S.A.
Brief Summary

The main objective of the study is to comparatively assess the efficacy and tolerability of the drugs under study in the treatment of acute uncomplicated cystitis.

Detailed Description

Urinary tract infections (UTI) are one of the most frequent reasons of surgery visits in Primary Care. More than 95 percent of UTIs are monomicrobial, although the microorganisms implied are varied, and the range of effective drugs could be extensive. The species most frequently isolated is Escherichia coli, with prevalence ranking between 85 and 90 percent of documented cases. E. coli has developed resistance to different antibiotics. Cefditoren is situated as a good candidate for the treatment of uncomplicated UTIs due to its spectrum of activity against E. coli. The study has been designed in accordance with the guidelines and recommendations in force to assess the efficacy of cefditoren pivoxil against ciprofloxacin, a drug which despite the increasing rate of resistance in some countries, continues to be a drug of choice for the treatment of uncomplicated UTIs.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
611
Inclusion Criteria
  • Non-pregnant adult females (>= 18)
  • Clinical signs and symptoms of uncomplicated acute cystitis (dysuria, urgency, frequency, suprapubic pain) with symptoms starting <=72 hours prior the study entry
  • Positive pre-treatment clean-catch midstream urine culture (>= 103 CFU/ml) and pyuria (10 leukocytes/mm3 or more than 5 leukocytes/field 40x magnification) within the 48 hours prior to inclusion in the study
  • In vitro susceptibility testing of the isolated uropathogen to the drugs under study
  • Written informed consent
Exclusion Criteria
  • Males
  • Woman who are pregnant, nursing or not using a medically accepted, effective method of birth control
  • Three or more episodes of uncomplicated acute infections of the urinary tract during the past 12 months
  • Symptoms starting >4 days prior to admission
  • Body temperature >= 38.3ยบC, back pain, chills or other manifestations suggestive of upper urinary infection
  • Evidence of structural or functional alterations of the urinary tract, such as calculi, stenosis, primary renal disease (eg. polycystic renal disease) or neurogenic bladder
  • Underlying disease predisposing to complicated urinary tract infections such as diabetes mellitus, immunosuppression, leucopenia, heart insufficiency, liver impairment and neoplastic processes

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
1cefditoren pivoxilCefditoren pivoxil
2CiprofloxacinCiprofloxacin
Primary Outcome Measures
NameTimeMethod
Microbiological efficacy5-9 days post-therapy
Secondary Outcome Measures
NameTimeMethod
Clinical efficacy5-9 days post-therapy

Trial Locations

Locations (30)

CAP Remei

๐Ÿ‡ช๐Ÿ‡ธ

Vic, Barcelona, Spain

CAP Florida Nord

๐Ÿ‡ช๐Ÿ‡ธ

Hospitalet de Llobregat, Barcelona, Spain

CS Basurto

๐Ÿ‡ช๐Ÿ‡ธ

Bilbao, Vizcaya, Spain

CAP Cornella

๐Ÿ‡ช๐Ÿ‡ธ

Cornella de Llobregat, Barcelona, Spain

CAP 17 setembre

๐Ÿ‡ช๐Ÿ‡ธ

El Prat de Llobregat, Barcelona, Spain

CAP Dr. Vicens Papaceit

๐Ÿ‡ช๐Ÿ‡ธ

La Roca del Valles, Barcelona, Spain

CS Torre Ramona

๐Ÿ‡ช๐Ÿ‡ธ

Zaragoza, Spain

CAP Les Bases-Manresa 3

๐Ÿ‡ช๐Ÿ‡ธ

Manresa, Barcelona, Spain

General Hospital of Thessaloniki

๐Ÿ‡ฌ๐Ÿ‡ท

Thessaloniki, Greece

CAP Bartomeu Fabres Anglada

๐Ÿ‡ช๐Ÿ‡ธ

Gava, Barcelona, Spain

CS Lucena

๐Ÿ‡ช๐Ÿ‡ธ

Lucena, Cordoba, Spain

CAP Amadeu Torner

๐Ÿ‡ช๐Ÿ‡ธ

Hospitalet de Llobregat, Barcelona, Spain

CAP La Riera

๐Ÿ‡ช๐Ÿ‡ธ

Mataro, Barcelona, Spain

CAP El Maresme

๐Ÿ‡ช๐Ÿ‡ธ

Mataro, Barcelona, Spain

General Hospital of Chest Disease of Athens

๐Ÿ‡ฌ๐Ÿ‡ท

Athens, Greece

CS Rincรณn de Loix

๐Ÿ‡ช๐Ÿ‡ธ

Benidorm, Alicante, Spain

CS San Telmo

๐Ÿ‡ช๐Ÿ‡ธ

Jerez de la frontera, Cadiz, Spain

CS Arrabal

๐Ÿ‡ช๐Ÿ‡ธ

Zaragoza, Spain

CAP Navas-Balsareny

๐Ÿ‡ช๐Ÿ‡ธ

Navas, Barcelona, Spain

CS Billabona

๐Ÿ‡ช๐Ÿ‡ธ

Billabona, Guipuzcoa, Spain

CS Legazpi

๐Ÿ‡ช๐Ÿ‡ธ

Legazpi, Guipuzcoa, Spain

CS Rute

๐Ÿ‡ช๐Ÿ‡ธ

Rute, Cordoba, Spain

CAP El Clot

๐Ÿ‡ช๐Ÿ‡ธ

Barcelona, Spain

CS Cabo Huertas

๐Ÿ‡ช๐Ÿ‡ธ

Alicante, Spain

CS Monzรณn Urbano

๐Ÿ‡ช๐Ÿ‡ธ

Monzon, Huesca, Spain

CS Sagasta Ruiseรฑores

๐Ÿ‡ช๐Ÿ‡ธ

Zaragoza, Spain

Fundacion Puigvert

๐Ÿ‡ช๐Ÿ‡ธ

Barcelona, Spain

CS Torrero La Paz

๐Ÿ‡ช๐Ÿ‡ธ

Zaragoza, Spain

CS Bombarda

๐Ÿ‡ช๐Ÿ‡ธ

Zaragoza, Spain

CS Cabra

๐Ÿ‡ช๐Ÿ‡ธ

Cabra, Cordoba, Spain

ยฉ Copyright 2025. All Rights Reserved by MedPath